Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Receivables (2020 - 2023)

Historic Receivables for Rocket Pharmaceuticals (RCKT) over the last 4 years, with Q4 2023 value amounting to $50000.0.

  • Rocket Pharmaceuticals' Receivables changed N/A to $50000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $50000.0, marking a year-over-year change of. This contributed to the annual value of $50000.0 for FY2023, which is N/A changed from last year.
  • Per Rocket Pharmaceuticals' latest filing, its Receivables stood at $50000.0 for Q4 2023.
  • Rocket Pharmaceuticals' Receivables' 5-year high stood at $1.6 million during Q2 2020, with a 5-year trough of $50000.0 in Q4 2023.
  • Moreover, its 4-year median value for Receivables was $1.0 million (2021), whereas its average is $964285.7.
  • Its Receivables has fluctuated over the past 5 years, first crashed by 3750.0% in 2021, then crashed by 1000.0% in 2022.
  • Quarter analysis of 4 years shows Rocket Pharmaceuticals' Receivables stood at $1.1 million in 2020, then decreased by 9.09% to $1.0 million in 2021, then decreased by 10.0% to $900000.0 in 2022, then plummeted by 94.44% to $50000.0 in 2023.
  • Its Receivables was $50000.0 in Q4 2023, compared to $900000.0 in Q1 2022 and $1.0 million in Q2 2021.